Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Apr 17;13:1189–1201. doi: 10.2147/DMSO.S248692

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Tang et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

(A) mRNA level of Blnc1 following treatment with Ad-GFP or Ad-Blnc1 adenovirus; (B) mtDNA content of 3T3-L1 pre-adipocytes; (C, D) expression of genes related to mitochondrial biogenesis and function by qRT-PCR; (E) ATP content; and (F – I) OCR. Dotted lines indicate injection of the respiratory inhibitors oligomycin (Oligo), FCCP, and rotenone and antimycin (R&A). (J) Representative TEM images of the mitochondrial ultrastructure of Ad-GFP and Blnc1-overpressing cells. Arrows and squares indicate mitochondria. Scale bars = 2, 1 μm. *p < 0.05, **p < 0.01, ***p < 0.001, Ad-GFP vs. Blnc1-over groups.